You are here

Lucentis

'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece

'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece

Fierce Pharma

Flag link:

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

Xconomy

AsclepiX Therapeutics

wet age-related macular degeneration

retinal occulsion

Flag link:

Biogen signs marketing deal for two ophthalmology biosimilars

Biogen signs marketing deal for two ophthalmology biosimilars

Pharmaforum

Samsung Bioepis

Flag link:

Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?

Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?

Endpoints

wet age-related macular degeneration

Molecular Partners

Flag link:

Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market

Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market

BioSpace

diabetic retinopathy

Flag link:

Novartis plans to file for new Lucentis indication in ROP

Novartis plans to file for new Lucentis indication in ROP

Pharmaceutical Business Review

retinopathy of prematurity

Flag link:

Roche, Novartis' Italian heads risk trial for alleged market rigging: sources

Roche, Novartis' Italian heads risk trial for alleged market rigging: sources

Yahoo/Reuters

marketing manipulation

Flag link:

Lucentis biosimilar: Formycon eyes 2020 for US launch

Lucentis biosimilar: Formycon eyes 2020 for US launch

BioPharma Reporter

Genentech/Roche

Flag link:

3 Big Pharma Companies With the Best Pipelines

3 Big Pharma Companies With the Best Pipelines

Motley Fool

Flag link:

Biotechs line up to tap growing ophthalmics market

Biotechs line up to tap growing ophthalmics market

BioPharma Dive

Ophthalmic Drugs Market

Ocular Therapeutix

Flag link:

Ophthotech Plunges on Eye Drug Study Failure

Ophthotech Plunges on Eye Drug Study Failure

TheStreet.com

clinical trials

wet age-related macular degeneration

Flag link:

9 Drugs That Cost Medicare a Fortune

9 Drugs That Cost Medicare a Fortune

Motley Fool

Flag link:

Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial

Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial

Bloomberg

dry eye disease

Flag link:

Lucentis more effective than lasers for reversing diabetes-induced blindness in new study

Lucentis more effective than lasers for reversing diabetes-induced blindness in new study

BioPharma Dive

proliferative diabetic retinopathy

Flag link:

The Next Blockbusters Could Be Balms For Aging Eyes

The Next Blockbusters Could Be Balms For Aging Eyes

Investors.com

age-related macular degeneration

Applied Genetic Technologies

Avalanche Biotechnologies

Flag link:

Eylea erodes Lucentis, Avastin market share

Eylea erodes Lucentis, Avastin market share

Medical Marketing and Media

Roche/Genentech

Flag link:

Biosimilar of Novartis' eye drug Lucentis launched in India

Biosimilar of Novartis' eye drug Lucentis launched in India

Fierce Pharma

Flag link:

Pfizer Buys Your Biosimilar Partner? How Pfenex’ Heartburn Was Quickly Relieved

Pfizer Buys Your Biosimilar Partner? How Pfenex’ Heartburn Was Quickly Relieved

Informabi

Flag link:

Did Novartis try to sabotage Avastin ophthalmic trials?

Did Novartis try to sabotage Avastin ophthalmic trials?

BioPharma Dive

Flag link:

BMJ: Novartis tried to 'scupper' trials to protect Lucentis from cheap Avastin

BMJ: Novartis tried to 'scupper' trials to protect Lucentis from cheap Avastin

Fierce Pharma

clinical trials

Flag link:

Pages